Enoblituzumab companion diagnostic - ImaginAb
Latest Information Update: 11 Sep 2012
At a glance
- Originator ImaginAb
- Developer ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 05 Sep 2012 Clinical trials in Cancer (diagnosis) in USA (Parenteral)